We further found SPRY4-IT1 was correlated with the prognosis of patients with CRC, and therefore thought SPRY4-IT1 had potential to regulate CRC progression and serve as a promising CRC molecular target. This evidence concerns the gene SPRY4 and colorectal carcinoma.